Stock Analysis on Net
Stock Analysis on Net
Microsoft Excel LibreOffice Calc

Bristol-Myers Squibb Co. (NYSE:BMY)

Analysis of Short-term (Operating) Activity Ratios
Quarterly Data

Beginner level

Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.

Short-term Activity Ratios (Summary)

Bristol-Myers Squibb Co., short-term (operating) activity ratios (quarterly data)

Microsoft Excel LibreOffice Calc
Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Turnover Ratios
Inventory turnover 4.45 3.49 1.88 6.15 5.48 5.31 5.48 5.09 5.20 5.19 5.20 4.62 4.53 3.72 3.99 3.05 3.00 3.08 3.20 — — —
Payables turnover 3.72 3.22 3.30 3.89 3.58 3.44 3.46 3.68 3.45 3.70 2.70 3.40 3.55 3.43 2.97 3.21 2.86 2.67 2.50 — — —
Working capital turnover 3.09 2.38 2.28 0.78 0.82 2.71 3.32 4.04 5.09 3.91 3.64 3.39 3.52 3.58 3.64 3.98 3.58 4.13 5.86 — — —
Average No. Days
Average inventory processing period 82 105 194 59 67 69 67 72 70 70 70 79 81 98 92 120 122 119 114 — — —
Less: Average payables payment period 98 113 110 94 102 106 105 99 106 99 135 107 103 106 123 114 127 137 146 — — —

Based on: 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-07), 10-K (filing date: 2020-02-24), 10-Q (filing date: 2019-10-31), 10-Q (filing date: 2019-07-25), 10-Q (filing date: 2019-04-25), 10-K (filing date: 2019-02-25), 10-Q (filing date: 2018-10-25), 10-Q (filing date: 2018-07-26), 10-Q (filing date: 2018-04-26), 10-K (filing date: 2018-02-13), 10-Q (filing date: 2017-10-26), 10-Q (filing date: 2017-07-27), 10-Q (filing date: 2017-04-27), 10-K (filing date: 2017-02-21), 10-Q (filing date: 2016-10-27), 10-Q (filing date: 2016-07-28), 10-Q (filing date: 2016-04-28), 10-K (filing date: 2016-02-12), 10-Q (filing date: 2015-10-27), 10-Q (filing date: 2015-07-23), 10-Q (filing date: 2015-04-28).

Short-term activity ratio Description The company
Inventory turnover An activity ratio calculated as cost of goods sold divided by inventory. Bristol-Myers Squibb Co.’s inventory turnover ratio improved from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.
Payables turnover An activity ratio calculated as cost of goods sold divided by payables. Bristol-Myers Squibb Co.’s payables turnover ratio decreased from Q4 2019 to Q1 2020 but then increased from Q1 2020 to Q2 2020 exceeding Q4 2019 level.
Working capital turnover An activity ratio calculated as revenue divided by working capital. Bristol-Myers Squibb Co.’s working capital turnover ratio improved from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.
Short-term activity ratio Description The company
Average inventory processing period An activity ratio equal to the number of days in the period divided by inventory turnover over the period. Bristol-Myers Squibb Co.’s number of days of inventory outstanding improved from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.
Average payables payment period An estimate of the average number of days it takes a company to pay its suppliers; equal to the number of days in the period divided by payables turnover ratio for the period. Bristol-Myers Squibb Co.’s number of days of payables outstanding increased from Q4 2019 to Q1 2020 but then decreased significantly from Q1 2020 to Q2 2020.

Inventory Turnover

Bristol-Myers Squibb Co., inventory turnover calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Selected Financial Data (US$ in millions)
Cost of products sold, excludes amortization of acquired intangible assets 2,699  3,662  2,432  1,810  1,992  1,844  1,690  1,648  1,625  1,584  1,673  1,572  1,562  1,259  1,383  1,305  1,206  1,052  952  1,097  1,013  847 
Inventories 2,384  2,836  4,293  1,192  1,308  1,283  1,195  1,282  1,242  1,231  1,166  1,250  1,217  1,384  1,241  1,482  1,437  1,336  1,221  1,130  1,304  1,437 
Short-term Activity Ratio
Inventory turnover1 4.45 3.49 1.88 6.15 5.48 5.31 5.48 5.09 5.20 5.19 5.20 4.62 4.53 3.72 3.99 3.05 3.00 3.08 3.20 — — —
Benchmarks
Inventory Turnover, Competitors2
Abbott Laboratories 2.56 2.92 3.07 2.96 2.94 3.13 3.35 3.38 3.36 3.23 3.43 3.27 3.00 2.49 3.71 3.41 3.15 3.16 3.37 — — —
AbbVie Inc. 2.36 4.17 4.10 3.86 3.89 4.40 4.81 4.47 4.91 4.23 4.39 3.54 3.92 4.26 4.04 3.53 3.08 2.75 2.62 — — —
Amgen Inc. 1.38 1.31 1.22 1.29 1.32 1.40 1.39 1.35 1.31 1.36 1.44 1.39 1.39 1.44 1.52 1.55 1.56 1.64 1.74 — — —
Biogen Inc. 1.83 2.10 2.43 2.66 2.61 2.56 1.95 2.00 1.87 1.90 1.81 1.49 1.65 1.68 1.48 1.42 1.33 1.29 1.39 — — —
Eli Lilly & Co. 1.48 1.55 1.48 1.62 1.70 1.96 1.56 1.57 1.56 1.36 1.36 1.34 1.32 1.40 1.59 1.44 1.44 1.38 1.46 — — —
Gilead Sciences Inc. 4.52 4.75 5.07 5.17 5.22 5.36 5.96 5.56 5.22 4.99 5.46 3.66 3.04 2.73 2.68 2.24 2.25 2.30 2.05 — — —
Illumina Inc. 2.29 2.74 3.00 2.55 2.53 2.55 2.68 2.65 2.67 2.69 2.78 2.72 2.71 2.63 2.44 2.28 2.23 2.37 2.48 — — —
Johnson & Johnson 2.93 3.16 3.05 2.99 2.93 2.98 3.15 3.15 3.14 2.95 2.89 2.48 2.29 2.45 2.66 2.57 2.53 2.64 2.67 — — —
Merck & Co. Inc. 2.33 2.46 2.36 2.35 2.29 2.34 2.48 2.52 2.56 2.41 2.51 2.41 2.37 2.59 2.85 2.75 2.81 2.93 3.18 — — —
Pfizer Inc. 1.15 1.21 1.23 1.30 1.31 1.38 1.50 1.40 1.43 1.39 1.48 1.41 1.51 1.61 1.82 1.67 1.53 1.41 1.28 — — —
Regeneron Pharmaceuticals Inc. 0.25 0.25 0.26 0.22 0.16 0.15 0.16 0.18 0.22 0.26 0.28 0.30 0.32 0.38 0.49 0.64 0.82 0.92 1.01 — — —
Vertex Pharmaceuticals Inc. 3.03 3.29 3.27 2.99 3.25 3.17 3.29 2.99 2.89 2.55 2.46 2.56 2.52 2.52 2.71 2.97 2.87 2.58 2.18 — — —
Zoetis Inc. 1.21 1.31 1.41 1.39 1.42 1.46 1.37 1.27 1.26 1.23 1.24 1.20 1.18 1.12 1.11 1.08 1.12 1.19 1.18 — — —

Based on: 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-07), 10-K (filing date: 2020-02-24), 10-Q (filing date: 2019-10-31), 10-Q (filing date: 2019-07-25), 10-Q (filing date: 2019-04-25), 10-K (filing date: 2019-02-25), 10-Q (filing date: 2018-10-25), 10-Q (filing date: 2018-07-26), 10-Q (filing date: 2018-04-26), 10-K (filing date: 2018-02-13), 10-Q (filing date: 2017-10-26), 10-Q (filing date: 2017-07-27), 10-Q (filing date: 2017-04-27), 10-K (filing date: 2017-02-21), 10-Q (filing date: 2016-10-27), 10-Q (filing date: 2016-07-28), 10-Q (filing date: 2016-04-28), 10-K (filing date: 2016-02-12), 10-Q (filing date: 2015-10-27), 10-Q (filing date: 2015-07-23), 10-Q (filing date: 2015-04-28).

1 Q2 2020 Calculation
Inventory turnover = (Cost of products sold, excludes amortization of acquired intangible assetsQ2 2020 + Cost of products sold, excludes amortization of acquired intangible assetsQ1 2020 + Cost of products sold, excludes amortization of acquired intangible assetsQ4 2019 + Cost of products sold, excludes amortization of acquired intangible assetsQ3 2019) ÷ Inventories
= (2,699 + 3,662 + 2,432 + 1,810) ÷ 2,384 = 4.45

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Inventory turnover An activity ratio calculated as cost of goods sold divided by inventory. Bristol-Myers Squibb Co.’s inventory turnover ratio improved from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.

Payables Turnover

Bristol-Myers Squibb Co., payables turnover calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Selected Financial Data (US$ in millions)
Cost of products sold, excludes amortization of acquired intangible assets 2,699  3,662  2,432  1,810  1,992  1,844  1,690  1,648  1,625  1,584  1,673  1,572  1,562  1,259  1,383  1,305  1,206  1,052  952  1,097  1,013  847 
Accounts payable 2,852  3,069  2,445  1,888  2,005  1,976  1,892  1,773  1,873  1,725  2,248  1,699  1,551  1,503  1,664  1,407  1,504  1,543  1,565  1,249  1,839  2,346 
Short-term Activity Ratio
Payables turnover1 3.72 3.22 3.30 3.89 3.58 3.44 3.46 3.68 3.45 3.70 2.70 3.40 3.55 3.43 2.97 3.21 2.86 2.67 2.50 — — —
Benchmarks
Payables Turnover, Competitors2
Abbott Laboratories 4.00 4.20 4.07 4.29 3.97 4.20 4.27 4.68 4.98 4.99 5.14 6.13 6.49 6.70 7.66 8.49 7.70 8.36 8.09 — — —
Amgen Inc. 4.60 3.60 3.18 4.18 4.20 3.86 3.40 3.90 3.92 3.69 3.01 4.64 4.66 4.59 4.54 5.05 4.80 5.15 4.38 — — —
Biogen Inc. 4.54 4.65 3.68 5.22 5.38 5.22 4.90 5.37 5.91 4.89 4.12 5.02 4.68 4.90 5.28 5.23 5.87 4.57 4.64 — — —
Eli Lilly & Co. 3.92 3.97 3.36 4.51 4.52 5.13 4.55 5.04 4.91 4.98 4.30 4.93 4.57 4.64 4.19 4.80 4.48 4.49 3.76 — — —
Gilead Sciences Inc. 8.93 7.94 6.56 7.22 7.48 8.33 6.14 7.83 7.20 6.21 5.37 6.02 5.23 4.26 3.53 4.04 3.73 4.57 3.40 — — —
Illumina Inc. 7.36 8.11 7.22 7.44 7.63 7.67 5.61 6.35 6.49 6.23 5.79 5.63 4.79 5.54 5.31 5.32 2.77 4.41 4.82 — — —
Johnson & Johnson 4.09 3.78 3.23 3.66 3.92 3.91 3.59 3.91 4.25 4.13 3.47 3.70 3.62 3.57 3.13 3.65 3.56 3.62 3.23 — — —
Merck & Co. Inc. 4.10 4.02 3.78 4.29 4.25 4.43 4.07 4.41 4.39 4.09 4.12 4.85 4.37 5.37 4.95 5.81 5.87 6.67 5.90 — — —
Pfizer Inc. 2.55 2.56 2.42 2.71 2.69 2.68 2.41 2.66 2.76 2.92 2.41 3.22 3.33 3.52 2.72 3.60 3.57 3.41 2.67 — — —
Regeneron Pharmaceuticals Inc. 1.07 1.06 0.87 0.89 0.87 0.76 0.82 1.10 1.19 1.01 1.14 — — — — — — — — — — —
Vertex Pharmaceuticals Inc. 6.54 6.11 6.25 5.24 6.03 5.26 3.69 4.03 4.01 4.05 3.72 3.26 3.06 3.27 3.42 4.19 3.73 2.17 1.66 — — —
Zoetis Inc. 5.73 7.29 6.62 7.06 6.90 8.43 6.11 7.66 7.77 8.20 6.80 8.38 8.85 7.45 6.29 7.03 7.61 8.25 5.93 — — —

Based on: 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-07), 10-K (filing date: 2020-02-24), 10-Q (filing date: 2019-10-31), 10-Q (filing date: 2019-07-25), 10-Q (filing date: 2019-04-25), 10-K (filing date: 2019-02-25), 10-Q (filing date: 2018-10-25), 10-Q (filing date: 2018-07-26), 10-Q (filing date: 2018-04-26), 10-K (filing date: 2018-02-13), 10-Q (filing date: 2017-10-26), 10-Q (filing date: 2017-07-27), 10-Q (filing date: 2017-04-27), 10-K (filing date: 2017-02-21), 10-Q (filing date: 2016-10-27), 10-Q (filing date: 2016-07-28), 10-Q (filing date: 2016-04-28), 10-K (filing date: 2016-02-12), 10-Q (filing date: 2015-10-27), 10-Q (filing date: 2015-07-23), 10-Q (filing date: 2015-04-28).

1 Q2 2020 Calculation
Payables turnover = (Cost of products sold, excludes amortization of acquired intangible assetsQ2 2020 + Cost of products sold, excludes amortization of acquired intangible assetsQ1 2020 + Cost of products sold, excludes amortization of acquired intangible assetsQ4 2019 + Cost of products sold, excludes amortization of acquired intangible assetsQ3 2019) ÷ Accounts payable
= (2,699 + 3,662 + 2,432 + 1,810) ÷ 2,852 = 3.72

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Payables turnover An activity ratio calculated as cost of goods sold divided by payables. Bristol-Myers Squibb Co.’s payables turnover ratio decreased from Q4 2019 to Q1 2020 but then increased from Q1 2020 to Q2 2020 exceeding Q4 2019 level.

Working Capital Turnover

Bristol-Myers Squibb Co., working capital turnover calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Selected Financial Data (US$ in millions)
Current assets 34,343  31,853  29,354  40,191  37,716  17,093  17,160  14,869  13,874  14,649  14,854  15,048  14,324  13,615  13,704  13,204  12,298  11,215  10,415  12,926  13,056  14,925 
Less: Current liabilities 23,421  19,232  18,304  10,489  9,711  8,841  10,654  9,694  9,878  9,624  9,563  9,438  9,017  8,494  8,841  8,996  7,885  7,597  8,017  7,158  7,435  7,689 
Working capital 10,922  12,621  11,050  29,702  28,005  8,252  6,506  5,175  3,996  5,025  5,291  5,610  5,307  5,121  4,863  4,208  4,413  3,618  2,398  5,768  5,621  7,236 
 
Net product sales 9,817  10,541  7,662  5,768  6,031  5,713  5,715  5,433  5,461  4,972  5,046  4,862  4,770  4,580  4,814  4,492  4,432  3,964  3,862  3,552  3,572  3,059 
Short-term Activity Ratio
Working capital turnover1 3.09 2.38 2.28 0.78 0.82 2.71 3.32 4.04 5.09 3.91 3.64 3.39 3.52 3.58 3.64 3.98 3.58 4.13 5.86 — — —
Benchmarks
Working Capital Turnover, Competitors2
Abbott Laboratories 5.02 6.84 6.64 5.57 5.04 5.80 5.44 5.61 5.72 4.78 2.44 1.87 1.79 1.76 1.04 4.45 4.76 5.08 4.11 — — —
AbbVie Inc. — 0.97 0.98 12.30 — 64.14 — 10.46 — 8.75 6.16 4.62 5.68 3.91 4.00 3.51 3.29 3.99 4.22 — — —
Amgen Inc. 1.87 3.27 3.96 1.10 1.11 1.00 0.93 0.85 0.82 0.73 0.54 0.53 0.54 0.61 0.63 0.61 0.67 0.63 0.70 — — —
Biogen Inc. 2.28 3.44 3.23 2.81 2.38 1.91 2.51 1.94 2.48 1.49 2.30 2.46 2.70 2.56 1.85 1.74 1.95 2.11 2.23 — — —
Eli Lilly & Co. 8.85 16.68 11.54 12.35 14.53 17.59 2.84 2.46 4.52 4.95 4.90 4.72 4.94 8.54 5.16 4.08 4.50 4.61 4.59 — — —
Gilead Sciences Inc. 1.55 1.24 1.08 1.17 0.89 0.89 0.86 0.88 1.04 1.24 1.27 1.05 1.40 2.18 2.67 3.01 4.04 3.88 2.16 — — —
Illumina Inc. 1.09 1.09 0.94 0.96 0.96 1.03 1.24 1.28 1.46 1.46 1.23 1.21 1.27 1.35 1.49 1.44 1.48 1.41 1.49 — — —
Johnson & Johnson 8.83 7.85 8.81 8.91 7.79 6.34 5.51 4.12 4.49 5.02 6.09 7.42 7.31 1.89 1.86 1.79 1.58 1.73 2.16 — — —
Merck & Co. Inc. 6.59 17.87 8.90 8.42 10.53 6.33 11.53 5.06 6.95 5.72 6.52 4.71 4.25 3.41 2.97 2.87 3.03 3.52 3.74 — — —
Pfizer Inc. 3.59 59.74 — — 3.57 3.39 2.97 4.25 10.34 7.05 4.90 4.35 5.69 4.78 6.74 14.23 4.45 4.06 3.39 — — —
Regeneron Pharmaceuticals Inc. 1.20 0.75 0.86 0.87 0.90 0.78 0.82 0.93 1.13 1.17 1.16 1.20 1.24 1.45 1.72 1.27 1.38 1.32 1.28 — — —
Vertex Pharmaceuticals Inc. 1.10 1.23 1.19 1.07 1.00 1.06 1.12 1.05 1.06 1.09 1.35 1.42 1.37 1.46 1.64 2.13 1.87 1.52 1.15 — — —
Zoetis Inc. 1.42 2.08 2.13 1.72 1.77 1.79 1.83 1.86 1.71 1.67 1.70 1.63 2.79 3.00 2.15 2.10 2.12 2.25 2.33 — — —

Based on: 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-07), 10-K (filing date: 2020-02-24), 10-Q (filing date: 2019-10-31), 10-Q (filing date: 2019-07-25), 10-Q (filing date: 2019-04-25), 10-K (filing date: 2019-02-25), 10-Q (filing date: 2018-10-25), 10-Q (filing date: 2018-07-26), 10-Q (filing date: 2018-04-26), 10-K (filing date: 2018-02-13), 10-Q (filing date: 2017-10-26), 10-Q (filing date: 2017-07-27), 10-Q (filing date: 2017-04-27), 10-K (filing date: 2017-02-21), 10-Q (filing date: 2016-10-27), 10-Q (filing date: 2016-07-28), 10-Q (filing date: 2016-04-28), 10-K (filing date: 2016-02-12), 10-Q (filing date: 2015-10-27), 10-Q (filing date: 2015-07-23), 10-Q (filing date: 2015-04-28).

1 Q2 2020 Calculation
Working capital turnover = (Net product salesQ2 2020 + Net product salesQ1 2020 + Net product salesQ4 2019 + Net product salesQ3 2019) ÷ Working capital
= (9,817 + 10,541 + 7,662 + 5,768) ÷ 10,922 = 3.09

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Working capital turnover An activity ratio calculated as revenue divided by working capital. Bristol-Myers Squibb Co.’s working capital turnover ratio improved from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.

Average Inventory Processing Period

Bristol-Myers Squibb Co., average inventory processing period calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Selected Financial Data
Inventory turnover 4.45 3.49 1.88 6.15 5.48 5.31 5.48 5.09 5.20 5.19 5.20 4.62 4.53 3.72 3.99 3.05 3.00 3.08 3.20 — — —
Short-term Activity Ratio (no. days)
Average inventory processing period1 82 105 194 59 67 69 67 72 70 70 70 79 81 98 92 120 122 119 114 — — —
Benchmarks (no. days)
Average Inventory Processing Period, Competitors2
Abbott Laboratories 142 125 119 123 124 116 109 108 109 113 107 112 122 147 98 107 116 115 108 — — —
AbbVie Inc. 155 88 89 94 94 83 76 82 74 86 83 103 93 86 90 103 118 133 139 — — —
Amgen Inc. 265 279 300 282 276 261 262 271 278 268 254 262 263 253 241 235 234 223 210 — — —
Biogen Inc. 200 173 150 137 140 143 187 182 195 192 202 245 221 217 247 257 274 284 263 — — —
Eli Lilly & Co. 247 236 247 225 214 186 233 233 235 268 268 272 276 260 230 254 253 264 250 — — —
Gilead Sciences Inc. 81 77 72 71 70 68 61 66 70 73 67 100 120 134 136 163 162 159 178 — — —
Illumina Inc. 160 133 122 143 144 143 136 138 137 136 131 134 134 139 150 160 164 154 147 — — —
Johnson & Johnson 124 116 119 122 125 122 116 116 116 124 126 147 159 149 137 142 144 138 136 — — —
Merck & Co. Inc. 156 148 155 156 160 156 147 145 142 152 146 151 154 141 128 133 130 125 115 — — —
Pfizer Inc. 317 302 296 281 279 264 244 261 254 262 246 258 242 227 201 219 238 259 284 — — —
Regeneron Pharmaceuticals Inc. 1,476 1,460 1,426 1,648 2,260 2,429 2,334 2,011 1,659 1,423 1,309 1,205 1,138 963 749 570 446 398 360 — — —
Vertex Pharmaceuticals Inc. 121 111 112 122 112 115 111 122 126 143 148 142 145 145 135 123 127 142 168 — — —
Zoetis Inc. 301 280 258 262 256 251 266 288 290 296 293 305 310 326 329 337 326 308 308 — — —

Based on: 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-07), 10-K (filing date: 2020-02-24), 10-Q (filing date: 2019-10-31), 10-Q (filing date: 2019-07-25), 10-Q (filing date: 2019-04-25), 10-K (filing date: 2019-02-25), 10-Q (filing date: 2018-10-25), 10-Q (filing date: 2018-07-26), 10-Q (filing date: 2018-04-26), 10-K (filing date: 2018-02-13), 10-Q (filing date: 2017-10-26), 10-Q (filing date: 2017-07-27), 10-Q (filing date: 2017-04-27), 10-K (filing date: 2017-02-21), 10-Q (filing date: 2016-10-27), 10-Q (filing date: 2016-07-28), 10-Q (filing date: 2016-04-28), 10-K (filing date: 2016-02-12), 10-Q (filing date: 2015-10-27), 10-Q (filing date: 2015-07-23), 10-Q (filing date: 2015-04-28).

1 Q2 2020 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ 4.45 = 82

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Average inventory processing period An activity ratio equal to the number of days in the period divided by inventory turnover over the period. Bristol-Myers Squibb Co.’s number of days of inventory outstanding improved from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.

Average Payables Payment Period

Bristol-Myers Squibb Co., average payables payment period calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Selected Financial Data
Payables turnover 3.72 3.22 3.30 3.89 3.58 3.44 3.46 3.68 3.45 3.70 2.70 3.40 3.55 3.43 2.97 3.21 2.86 2.67 2.50 — — —
Short-term Activity Ratio (no. days)
Average payables payment period1 98 113 110 94 102 106 105 99 106 99 135 107 103 106 123 114 127 137 146 — — —
Benchmarks (no. days)
Average Payables Payment Period, Competitors2
Abbott Laboratories 91 87 90 85 92 87 85 78 73 73 71 60 56 54 48 43 47 44 45 — — —
Amgen Inc. 79 101 115 87 87 95 107 94 93 99 121 79 78 80 80 72 76 71 83 — — —
Biogen Inc. 80 79 99 70 68 70 74 68 62 75 89 73 78 74 69 70 62 80 79 — — —
Eli Lilly & Co. 93 92 109 81 81 71 80 72 74 73 85 74 80 79 87 76 81 81 97 — — —
Gilead Sciences Inc. 41 46 56 51 49 44 59 47 51 59 68 61 70 86 103 90 98 80 107 — — —
Illumina Inc. 50 45 51 49 48 48 65 57 56 59 63 65 76 66 69 69 132 83 76 — — —
Johnson & Johnson 89 97 113 100 93 93 102 93 86 88 105 99 101 102 116 100 103 101 113 — — —
Merck & Co. Inc. 89 91 97 85 86 82 90 83 83 89 89 75 83 68 74 63 62 55 62 — — —
Pfizer Inc. 143 143 151 135 136 136 152 137 132 125 151 113 110 104 134 101 102 107 137 — — —
Regeneron Pharmaceuticals Inc. 342 343 421 411 419 481 442 333 307 360 321 — — — — — — — — — — —
Vertex Pharmaceuticals Inc. 56 60 58 70 61 69 99 91 91 90 98 112 119 111 107 87 98 169 220 — — —
Zoetis Inc. 64 50 55 52 53 43 60 48 47 45 54 44 41 49 58 52 48 44 62 — — —

Based on: 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-07), 10-K (filing date: 2020-02-24), 10-Q (filing date: 2019-10-31), 10-Q (filing date: 2019-07-25), 10-Q (filing date: 2019-04-25), 10-K (filing date: 2019-02-25), 10-Q (filing date: 2018-10-25), 10-Q (filing date: 2018-07-26), 10-Q (filing date: 2018-04-26), 10-K (filing date: 2018-02-13), 10-Q (filing date: 2017-10-26), 10-Q (filing date: 2017-07-27), 10-Q (filing date: 2017-04-27), 10-K (filing date: 2017-02-21), 10-Q (filing date: 2016-10-27), 10-Q (filing date: 2016-07-28), 10-Q (filing date: 2016-04-28), 10-K (filing date: 2016-02-12), 10-Q (filing date: 2015-10-27), 10-Q (filing date: 2015-07-23), 10-Q (filing date: 2015-04-28).

1 Q2 2020 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ 3.72 = 98

2 Click competitor name to see calculations.

Short-term activity ratio Description The company
Average payables payment period An estimate of the average number of days it takes a company to pay its suppliers; equal to the number of days in the period divided by payables turnover ratio for the period. Bristol-Myers Squibb Co.’s number of days of payables outstanding increased from Q4 2019 to Q1 2020 but then decreased significantly from Q1 2020 to Q2 2020.